Literature DB >> 25554580

Deltonin inhibits angiogenesis by regulating VEGFR2 and subsequent signaling pathways in endothelial cells.

Qingyi Tong1, Qingbing Zhao1, Yong Qing2, Xiaojuan Hu2, Lei Jiang2, Xiaohua Wu3.   

Abstract

Deltonin is a steroidal saponin which could suppress tumor growth through suppressing angiogenesis, but the mechanisms have not been directly elucidated yet. In the present study, we showed that deltonin inhibited the proliferation of primary cultured human umbilical vein endothelial cells (HUVECs) in vitro; notably, it could significantly inhibit HUVECs migration, invasion, and tube formation, which are indispensable progresses of angiogenesis. We further demonstrated that deltonin could inhibit VEGF-induced blood vessel formation in vivo. What is more, we found that deltonin blocked VEGF triggered phosphorylation of key intracellular angiogenic molecules, such as VEGFR2, Src family kinase, focal adhesion kinase (FAK), extracellular signal-related kinase (Erk1/2) and AKT kinase, accompanied with the increase of phosphorylated P38MAPK. Taken together, the present study demonstrates that deltonin inhibits angiogenesis through regulating VEGFR2 signaling pathway as well as AKT/MAPK signaling pathways in endothelial cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKT/MAPK; Antiangiogenesis; Deltonin; HUVECs; VEGFR2

Mesh:

Substances:

Year:  2014        PMID: 25554580     DOI: 10.1016/j.steroids.2014.12.019

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  2 in total

1.  Structural Determinant and Its Underlying Molecular Mechanism of STPC2 Related to Anti-Angiogenic Activity.

Authors:  Min Hu; Ning Cui; Zhixiang Bo; Feixiang Xiang
Journal:  Mar Drugs       Date:  2017-02-21       Impact factor: 5.118

2.  Ginsenoside Rb1 prevents homocysteine-induced EPC dysfunction via VEGF/p38MAPK and SDF-1/CXCR4 activation.

Authors:  Tao-Hua Lan; Dan-Ping Xu; Man-Ting Huang; Ju-Xian Song; Huan-Lin Wu; Min Li
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.